Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Covidien Receives FDA Approval for South African-Produced Medical Isotope Based on Low-Enriched Uranium

March 11, 2011 By Covidien

ST. LOUIS, Mar 10, 2011 (BUSINESS WIRE) —

Covidien (NYSE: COV), a leading global provider of healthcare
products, today announced that the U.S. Food and Drug
Administration (FDA) has approved the use of molybdenum-99 (Mo-99)
derived from low-enriched uranium (LEU) in the production of
technetium-99m (Tc-99m) generators. Tc-99m is a medical isotope,
utilized in over 80% of all nuclear medicine studies, supplied to
hospitals and nuclear pharmacies by Covidien’s Mallinckrodt
business.

Tc-99m is produced when Mo-99 decays following uranium
irradiation. The approval by the FDA allows use of LEU-based Mo-99
supplied by South Africa’s NTP Radioisotopes, Ltd., a subsidiary of
the Nuclear Energy Corporation of South Africa, in Tc-99m generator
production at Covidien’s Maryland Heights, MO, manufacturing
facility.

Tc-99m is a critical medical isotope used in diagnostic and
functional studies of organs and anatomical systems. The
information from these studies is used by many medical specialists
(including radiologists, cardiologists, nephrologists and
oncologists) to better diagnose and treat patients. More than 30
million nuclear medicine procedures are performed worldwide each
year using Tc-99m, more than half in the United States.

“This FDA approval represents another step in our commitment to
move toward LEU conversion in the production of Mo-99 and Tc-99m,”
said Elaine Haynes, Vice President and General Manager, Imaging,
Americas.

In January, 2009, the Company launched a collaborative effort
with Babcock & Wilcox Technical Services Group (B&W) to
develop solution-based reactor technology for LEU-based medical
isotope production, a unique approach designed to provide an
efficient domestic supply source. The project combines Covidien’s
expertise in radiopharmaceutical production and global regulatory
approvals with B&W’s patented liquid phase nuclear technology.
Covidien is also developing plans for conversion of its Mo-99
processing facility in Petten, the Netherlands, to facilitate use
of LEU.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that
creates innovative medical solutions for better patient outcomes
and delivers value through clinical leadership and excellence.
Covidien manufactures, distributes and services a diverse range of
industry-leading product lines in three segments: Medical Devices,
Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4
billion, Covidien has approximately 42,000 employees worldwide in
more than 60 countries, and its products are sold in over 140
countries. Please visit
www.covidien.com
to learn more about our business.

Forward Looking Statements

Any statements contained in this communication that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on our management’s current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or Company actions to
differ materially from what is expressed or implied by these
statements. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, our ability to effectively introduce and market new
products or keep pace with advances in technology, the
reimbursement practices of a small number of large public and
private insurers, cost-containment efforts of customers, purchasing
groups, third-party payors and governmental organizations,
intellectual property rights disputes, complex and costly
regulation, including healthcare fraud and abuse regulations and
the Foreign Corrupt Practices Act, manufacturing or supply chain
problems or disruptions, rising commodity costs, recalls or safety
alerts and negative publicity relating to Covidien or its products,
product liability losses and other litigation liability,
divestitures of some of our businesses or product lines, our
ability to execute strategic acquisitions of, investments in or
alliances with other companies and businesses, competition, risks
associated with doing business outside of the United States,
foreign currency exchange rates and environmental remediation
costs. These and other factors are identified and described in more
detail in our Annual Report on Form 10-K for the fiscal year ended
September 24, 2010, and in subsequent filings with the SEC. We
disclaim any obligation to update these forward-looking statements
other than as required by law.

SOURCE

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe